Overview

Using Behavioral Therapy in Combination With Darifenacin for Symptoms of Overactive Bladder

Status:
Completed
Trial end date:
2006-02-01
Target enrollment:
0
Participant gender:
All
Summary
This study is designed to investigate the efficacy and safety of treatment of overactive bladder with darifenacin administered alone or in conjunction with behavioral modification therapies.
Phase:
Phase 4
Details
Lead Sponsor:
Novartis
Collaborator:
Procter and Gamble
Treatments:
Darifenacin
Criteria
Inclusion Criteria:

- Symptoms of overactive bladder

- Capable of independent toileting and completing a micturition diary

- Able to comprehend English and follow study procedures and instructions

Exclusion Criteria:

- Post void residual > 100ml/sec

- Urine flow rate (Qmax) <10ml/sec for males only

Other protocol-defined inclusion/exclusion criteria may apply